Risk Factors Associated with Venous Thromboembolism in Breast Cancer: a Narrative Review

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2022 May 5

PMID 35511300

Authors

Zayd Adnan Razouki

Nadeen T Ali

Vinh Q Nguyen

Carmen P Escalante

Affiliations

Soon will be listed here.

Abstract

Purpose: To date, there is no universally acceptable risk assessment tool in clinical practice that accurately estimates the risk of venous thromboembolism (VTE) in patients with breast cancer, despite the large number of published studies. Thus, the aim of this narrative review was to summarize the most relevant risk factors for VTE in these patients.

Methods: We searched Ovid Embase and Ovid MEDLINE, from inception to March 26, 2021, to identify all articles that focused on breast cancer and multiple thromboembolic diseases. We also searched the references section of relevant articles to identify studies. We did not include case reports or case series with small sample size, N < 20.

Results: VTE in patients with breast cancer was strongly associated with patient-, tumor-, and non-tumor-related risk factors, such as age, disease stage, central catheter placement, and chemotherapy and tamoxifen use, especially within 2 years of breast cancer diagnosis. CDK inhibitors are emerging factors that may also increase the risk of VTE.

Conclusions: The risk of VTE in patients with breast cancer depends on various patient-, tumor-, and non-tumor-related risk factors. Identifying these risk factors during breast cancer diagnosis and treatment is essential in developing a practical dynamic predictive tool that can help individualize strategies to prevent VTE.

Citing Articles

Cerebral venous sinus thrombosis in a patient treated with ribociclib for metastatic breast cancer. Case reports and literature review.

Sharaf B, Othman Z, Abu Faris H, Al-Bitar M, Al-Zoubi Q, Abu Laban D SAGE Open Med Case Rep. 2024; 12:2050313X241233190.

PMID: 38390439 PMC: 10883115. DOI: 10.1177/2050313X241233190.

No evidence for a genetic causal effect of breast cancer on venous thromboembolism: a mendelian randomization study.

Qin Q, Pan Y, Wang L J Thromb Thrombolysis. 2023; 57(1):117-123.

PMID: 37615800 DOI: 10.1007/s11239-023-02871-1.

Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry.

Ohsumi S, Watanabe K, Kondo N, Kosaka Y, Ishikawa T, Kitahara M Breast Cancer. 2023; 30(4):607-616.

PMID: 37069366 PMC: 10284999. DOI: 10.1007/s12282-023-01452-7.

Development and validation of a machine learning model to predict venous thromboembolism among hospitalized cancer patients.

Meng L, Wei T, Fan R, Su H, Liu J, Wang L Asia Pac J Oncol Nurs. 2022; 9(12):100128.

PMID: 36276886 PMC: 9583033. DOI: 10.1016/j.apjon.2022.100128.

References

Walker A, Card T, West J, Crooks C, Grainge M . Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer. 2012; 49(6):1404-13. DOI: 10.1016/j.ejca.2012.10.021. View

Khorana A, Francis C, Culakova E, Fisher R, Kuderer N, Lyman G . Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006; 24(3):484-90. DOI: 10.1200/JCO.2005.03.8877. View

Paneesha S, McManus A, Arya R, Scriven N, Farren T, Nokes T . Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics. Thromb Haemost. 2009; 103(2):338-43. DOI: 10.1160/TH09-06-0397. View

Reboucas D, Costa M, Thuler L, Garces A, Aquino L, Bines J . Breast cancer-associated venous thromboembolism: A case-control study. Breast. 2016; 28:84-8. DOI: 10.1016/j.breast.2016.04.015. View

Shai A, Rennert H, Lavie O, Ballan-Haj M, Bitterman A, Steiner M . Statins, aspirin and risk of venous thromboembolic events in breast cancer patients. J Thromb Thrombolysis. 2013; 38(1):32-8. DOI: 10.1007/s11239-013-1015-8. View

Brand J, Hedayati E, Bhoo-Pathy N, Bergh J, Hall P, Humphreys K . Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study. Cancer. 2016; 123(3):468-475. DOI: 10.1002/cncr.30364. View

Chavez-MacGregor M, Zhao H, Kroll M, Fang S, Zhang N, Hortobagyi G . Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. Ann Oncol. 2011; 22(11):2394-2402. PMC: 3200221. DOI: 10.1093/annonc/mdq777. View

Clahsen P, van de Velde C, Julien J, Floiras J, Mignolet F . Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol. 1994; 12(6):1266-71. DOI: 10.1200/JCO.1994.12.6.1266. View

Saphner T, Tormey D, Gray R . Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991; 9(2):286-94. DOI: 10.1200/JCO.1991.9.2.286. View

10.

Onitilo A, Doi S, Engel J, Glurich I, Johnson J, Berg R . Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience. Thromb Res. 2011; 130(1):27-31. PMC: 4154055. DOI: 10.1016/j.thromres.2011.11.025. View

11.

Hernandez R, Sorensen H, Pedersen L, Jacobsen J, Lash T . Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer. 2009; 115(19):4442-9. DOI: 10.1002/cncr.24508. View

12.

Kovac M, Kovac Z, Tomasevic Z, Vucicevic S, Djordjevic V, Pruner I . Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study. Eur J Intern Med. 2015; 26(1):63-7. DOI: 10.1016/j.ejim.2014.12.015. View

13.

Mandala M, Curigliano G, Bucciarelli P, Ferretti G, Mannucci P, Colleoni M . Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol. 2004; 15(4):590-3. DOI: 10.1093/annonc/mdh146. View

14.

Tan L, Sun Y, Zhu L, Lei X, Liang D, Rao N . Risk factors of catheter-related thrombosis in early-stage breast cancer patients: a single-center retrospective study. Cancer Manag Res. 2019; 11:8379-8389. PMC: 6750851. DOI: 10.2147/CMAR.S212375. View

15.

Kang J, Sun W, Li H, Ma E, Wang K, Chen W . Peripherally inserted central catheter-related vein thrombosis in breast cancer patients. J Vasc Access. 2015; 17(1):67-71. DOI: 10.5301/jva.5000457. View

16.

Debourdeau P, Espie M, Chevret S, Gligorov J, Elias A, Dupre P . Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study. Cancer Med. 2017; 6(11):2732-2744. PMC: 5673948. DOI: 10.1002/cam4.1201. View

17.

Eggemann H, Bernreiter A, Reinisch M, Loibl S, Taran F, Costa S . Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis. Br J Cancer. 2019; 120(3):301-305. PMC: 6353985. DOI: 10.1038/s41416-018-0369-2. View

18.

Faiz A, Guo S, Kaveney A, Philipp C . Venous thrombosis and breast cancer in older women: Racial differences in risk factors and mortality. Thromb Res. 2018; 171:130-135. DOI: 10.1016/j.thromres.2018.10.002. View

19.

West M, Smith C, Kaempf A, Kohs T, Amirsoltani R, Ribkoff J . CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. Eur J Haematol. 2021; 106(5):634-642. PMC: 8087188. DOI: 10.1111/ejh.13590. View

20.

Pritchard K, Paterson A, Paul N, Zee B, Fine S, Pater J . Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996; 14(10):2731-7. DOI: 10.1200/JCO.1996.14.10.2731. View